Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$44.39M, compared with -$34.07M a year earlier.
Context
- Net debt amounted to 12.8% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -30.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (191.09M) USD
- Year-over-year change
- -285.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (191.09M) | -285.4% |
| FY2024 | 2024-12-31 | (49.58M) | -236.3% |
| FY2023 | 2023-12-31 | (14.74M) | +32.0% |
| FY2022 | 2022-12-31 | (21.68M) | +38.8% |
| FY2021 | 2021-12-31 | (35.41M) | — |
Net Debt vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's Mar 2026 net debt of -$44.39M is the 5th highest of the 10 companies compared; the peer median is -$45.38M.
- Its year-over-year change of -30.3% is the 6th highest of 10, against a peer median of -24.8%.
- Net debt amounts to 12.8% of total assets for FULC, versus a peer median of 39.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.73M | -24.8% | -11.5% | 107.9% | |
| Mar 2026 | $19.62M | -54.8% | +46.1% | 7.3% | |
| Mar 2026 | $1.44M | +124.1% | — | 2.5% | |
| Mar 2026 | -$33.55M | +26.5% | — | 30.6% | |
| Mar 2026 | -$44.39M | -30.3% | — | 12.8% | |
| Mar 2026 | -$45.38M | -30.9% | — | 22.1% | |
| Mar 2026 | -$114.34M | -144.8% | — | 39.2% | |
| Mar 2026 | -$115.03M | -101.0% | — | 43.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
| Mar 2026 | -$544.14M | +30.6% | — | 83.4% | |
| Peer median (excluding FULC) | -$45.38M | -24.8% | +17.3% | 39.2% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.41M | 35.1M | 25.56M | 58.21M | 197.53M |
| Short-term Investments | 182.75M | 167.82M | 210.66M | 182.81M | 154.77M |
| Net Receivables | 4.11M | 1.08M | 2.25M | 3.34M | 1.07M |
| Inventory | (473K) | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 5.17M |
| Total Current Assets | 226M | 207.52M | 242.2M | 249.92M | 357.48M |
| Property, Plant & Equipment (Net) | 7.37M | 15.97M | 12.39M | 9.58M | 7.07M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.09M | 1.09M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 542K | 2.1M | 3.1M | 1.21M | 1.74M |
| Total Non-current Assets | 9M | 19.17M | 15.5M | 10.8M | 8.8M |
| Total Assets | 235M | 226.69M | 257.69M | 260.72M | 366.28M |
| Account Payables | 4.79M | 3.64M | 2.76M | 1.16M | 1.59M |
| Short-term Debt | 0 | 2.6M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.71M | 934K | 0 | 0 | 0 |
| Other Current Liabilities | 4.71M | 5.34M | 396K | 463K | 258K |
| Total Current Liabilities | 19.2M | 16.73M | 13.68M | 11.04M | 13.05M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 197K | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.26M | 0 | 197K | 197K | 197K |
| Total Non-current Liabilities | 4.26M | 11.02M | 8.83M | 6.64M | 4.24M |
| Total Liabilities | 23.46M | 27.74M | 22.5M | 17.68M | 17.28M |
| Common Stock | 41K | 52K | 62K | 54K | 67K |
| Retained Earnings | (302.47M) | (412.34M) | (509.67M) | (519.4M) | (594.28M) |
| Accumulated OCI | (397K) | (797K) | (136K) | 130K | 174K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 211.54M | 198.94M | 235.19M | 243.03M | 349M |
| Total Debt | 0 | 13.42M | 10.82M | 8.63M | 6.44M |
| Net Debt | (35.41M) | (21.68M) | (14.74M) | (49.58M) | (191.09M) |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.